Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA6 | P23280 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532953 | 1.00 | GSR (0.41) | GSRTRPV1TRPA1NFKB1DNM1 | |
| SCHEMBL727485 | 0.92 | — | — | |
| SCHEMBL21973386 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL5463908 | 0.89 | TRPV1 (0.35) | GSRTRPV1TRPA1NFKB1DNM1 | |
| SCHEMBL3689551 | 0.88 | OPRM1 (0.43) | TRPV1TRPA1LMNATSHRBLM | |
| SCHEMBL11119184 | 0.85 | TRPV1 (0.46) | TRPV1TRPA1LMNABLMOPRM1 | |
| SCHEMBL10356278 | 0.85 | TRPV1 (0.46) | TRPV1TRPA1LMNABLMOPRM1 | |
| SCHEMBL28494392 | 0.84 | GSR (0.38) | GSRTRPV1TRPA1NFKB1DNM1 | |
| SCHEMBL30509013 | 0.83 | TRPV1 (0.46) | GSRTRPV1TRPA1NFKB1DNM1 | |
| SCHEMBL30509012 | 0.83 | TRPV1 (0.46) | GSRTRPV1TRPA1NFKB1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024008939-A1 | COMPOSITIONS FOR FIBREBOARDS WITH ENHANCED PROPERTIES UPON FAST-CURING AT LOW TEMPERATURE | COVESTRO (NETHERLANDS) B.V. (NL) | 2024-01-11 | — | — | WO | disclosed |
| WO-2022096518-A1 | COMPOSITIONS SUITABLE FOR ENHANCING THE FLEXURAL PROPERTIES OF OBJECTS CONTAINING VEGETABLE FIBERS | COVESTRO (NETHERLANDS) B.V. (NL) | 2022-05-12 | — | — | WO | disclosed |
| US-20210040069-A1 | DACOS Type NNRTIS Amino Acid Ester Derivative, Preparation Method Thereof, Pharmaceutical Composition, and Application Thereof | YUNNAN UNIVERSITY (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2017019833-A1 | COMPOSITIONS CONTAINING REPAIR CELLS AND CATIONIC DYES | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2014-05-15 | — | — | US | disclosed |
| CN-101516948-B | Diamine chain extender compositions | ALBEMARLE CORP | 2012-08-15 | — | — | CN | disclosed |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | MCLAURIN JOANNE | 2011-05-05 | — | — | US | disclosed |
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | MCLAURIN JOANNE | 2010-12-30 | — | — | US | disclosed |
| US-20100292157-A1 | Combination Treatments for Alzheimer's Disease and Similar Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100144891-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | MCLAURIN JOANNE | 2010-06-10 | — | — | US | disclosed |
| US-20100113613-A1 | CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION | WARATAH PHARMACEUTICALS (CA) | 2010-05-06 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| CN-101516948-A | Diamine chain extender compositions | ALBEMARLE CORP (US) | 2009-08-26 | — | — | CN | disclosed |
| CN-101516944-A | Chain extenders | ALBEMARLE CORP (US) | 2009-08-26 | — | — | CN | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | SNCA, PARK7, PMP22 | GSR 528/4885TRPV1 1417/4885TRPA1 1053/4885 |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | CDR2, HYPK, HTT | GSR 886/4885TRPV1 3639/4885TRPA1 3625/4885 |
| US-20210040069-A1 | DACOS Type NNRTIS Amino Acid Ester Derivative, Preparation Method Thereof, Pharmaceutical Composition, and Application Thereof | DAO, ASNS, DDO | GSR 4706/4885TRPV1 4741/4885TRPA1 4863/4885 |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | APP, IAPP, TTR | GSR 619/4885TRPV1 1053/4885TRPA1 230/4885 |
| US-20100292157-A1 | Combination Treatments for Alzheimer's Disease and Similar Diseases | APP, PSEN1, BACE1 | GSR 1282/4885TRPV1 2986/4885TRPA1 2449/4885 |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | GSR 675/4885TRPV1 2420/4885TRPA1 1561/4885 |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | HTT, APP, PSEN2 | GSR 2684/4885TRPV1 322/4885TRPA1 57/4885 |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | SCLY, SCO2, SGMS2 | GSR 723/4885TRPV1 2403/4885TRPA1 1639/4885 |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | APP, IAPP, TTR | GSR 571/4885TRPV1 1132/4885TRPA1 261/4885 |
| US-20100144891-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SOD1, SOD3, SMN1; SMN2 | GSR 234/4885TRPV1 2344/4885TRPA1 690/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | GSR 741/4885TRPV1 2418/4885TRPA1 1600/4885 |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | SCLY, SMOX, SMS | GSR 675/4885TRPV1 2420/4885TRPA1 1561/4885 |
| US-20100113613-A1 | CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION | APP, MAPT, HTT | GSR 4415/4885TRPV1 1663/4885TRPA1 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.